M&A Deal Summary

Pyxis Oncology Acquires Apexigen

On August 23, 2023, Pyxis Oncology acquired life science company Apexigen

Acquisition Highlights
  • This is Pyxis Oncology’s 1st transaction in the Life Science sector.
  • This is Pyxis Oncology’s 1st transaction in the United States.
  • This is Pyxis Oncology’s 1st transaction in California.

M&A Deal Summary

Date 2023-08-23
Target Apexigen
Sector Life Science
Buyer(s) Pyxis Oncology
Deal Type Add-on Acquisition
Advisor(s) Ladenburg Thalmann & Co. (Financial)
Wilson Sonsini Goodrich & Rosati (Legal)

Target

Apexigen

San Carlos, California, United States
Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is currently in clinical development, and also includes several preclinical stage immune-oncology programs. Apexigen was founded in 2010 and is based in San Carlos, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Pyxis Oncology

Boston, Massachusetts, United States

Category Company
Founded 2018
Sector Life Science
Employees44
Revenue 16M USD (2024)
DESCRIPTION

Pyxis Oncology specializes in developing a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis Oncology was founded in 2018 and is based in Boston, Massachusetts.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2023 M&A 1 of 1